Share on StockTwits

Trivascular Technologies (NASDAQ:TRIV) announced its earnings results on Wednesday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.21, ARN reports. The company had revenue of $7.80 million for the quarter, compared to the consensus estimate of $7.54 million. The company’s revenue for the quarter was up 61.5% on a year-over-year basis.

Trivascular Technologies (NASDAQ:TRIV) traded up 8.21% during mid-day trading on Wednesday, hitting $14.36. The stock had a trading volume of 51,273 shares. Trivascular Technologies has a 52 week low of $11.15 and a 52 week high of $17.99. The stock’s 50-day moving average is $15.34 and its 200-day moving average is $15.05. The company’s market cap is $277.6 million.

Several analysts have recently commented on the stock. Analysts at Canaccord Genuity initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set a “buy” rating and a $20.00 price target on the stock. On the ratings front, analysts at JPMorgan Chase & Co. initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set an “overweight” rating and a $18.00 price target on the stock. Finally, analysts at Stifel Nicolaus initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set a “buy” rating and a $17.00 price target on the stock. They noted that the move was a valuation call.

Trivascular Technologies, Inc is a medical device company. The Company is developing and commercializing technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms (NASDAQ:TRIV).

Receive News & Ratings for Trivascular Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trivascular Technologies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.